KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Weighted Average): 2013-2024

Historic Shares Outstanding (Weighted Average) for Esperion Therapeutics (ESPR) over the last 12 years, with Dec 2024 value amounting to $197.0 million.

  • Esperion Therapeutics' Shares Outstanding (Weighted Average) rose 2.75% to $201.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $201.6 million, marking a year-over-year increase of 2.75%. This contributed to the annual value of $197.0 million for FY2024, which is 73.27% up from last year.
  • Per Esperion Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $197.0 million for FY2024, which was up 73.27% from $113.7 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $197.0 million in FY2024 and a low of $27.9 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $128.1 million, with a median of $113.7 million in 2023.
  • Data for Esperion Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 153.41% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Shares Outstanding (Weighted Average) stood at $27.9 million in 2020, then increased by 4.31% to $29.1 million in 2021, then spiked by 153.41% to $73.7 million in 2022, then skyrocketed by 54.33% to $113.7 million in 2023, then soared by 73.27% to $197.0 million in 2024.